ESSA Pharma Inc (NAS:EPIX)

$ 6.2 0 (0%) Market Cap: 275.05 Mil Enterprise Value: 139.52 Mil PE Ratio: 0 PB Ratio: 2.06 GF Score: 42/100

ESSA Pharma Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
ESSA Pharma Inc at JMP Securities Life Sciences Conference Transcript
May 16, 2023
ESSA Pharma Inc at Bloom Burton & Co Healthcare Investor Conference Transcript
Apr 25, 2023
ESSA Pharma Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 15, 2023
ESSA Pharma Inc at Guggenheim Healthcare Talks Oncology Day Transcript
Feb 09, 2023
ESSA Pharma Inc at Piper Sandler Healthcare Conference Transcript
Nov 29, 2022
ESSA Pharma Inc at Jefferies London Healthcare Conference Transcript
Nov 17, 2022
ESSA Pharma Inc at Bloom Burton & Co. Healthcare Investor Conference Transcript
May 02, 2022

ESSA Pharma Inc at Bloom Burton & Co. Healthcare Investor Conference Transcript

May 02, 2022 / 06:30PM GMT

Transcript 8-K10-Q

David Parkinson

ESSA Pharma Inc. - President, CEO & Director

Appreciate the opportunity to tell you where we are at. We will be giving a detailed update on clinical data to date at the end of June, so stay tuned for all of that. But in the meantime, I will take you through the story, take you where we are at, what we are trying to achieve, where we stand so far, and the likely path as we go forward into the future.

So as many of you know, ESSA was formed on biology and chemistry that came out of the University of British Columbia and the British Columbia Cancer Agency back in the early 2000s. And what is novel about what we are doing is we are working with a series of molecules that were developed by ESSA called Anitens. And what's unique about them is they shut down androgen-driven biology and do so from the N-terminal domain of the receptor.

Now all the antiandrogens which have -- and antiandrogen approaches which have been developed over the last six decades -- that's almost 70 years -- have involved the other end of the receptor, the ligand-binding domain. I will go in through

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.